Cargando…

Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors

Longitudinal changes in pancreatic neuroendocrine tumor (panNET) cell proliferation correlate with fast disease progression and poor prognosis. The optimal treatment strategy for secondary panNET grade (G)3 that has progressed from a previous low- or intermediate-grade to high-grade panNET G3 is cur...

Descripción completa

Detalles Bibliográficos
Autores principales: Mollazadegan, Kazhan, Skogseid, Britt, Botling, Johan, Åkerström, Tobias, Eriksson, Barbro, Welin, Staffan, Sundin, Anders, Crona, Joakim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942326/
https://www.ncbi.nlm.nih.gov/pubmed/35148276
http://dx.doi.org/10.1530/EC-21-0604
_version_ 1784673285379719168
author Mollazadegan, Kazhan
Skogseid, Britt
Botling, Johan
Åkerström, Tobias
Eriksson, Barbro
Welin, Staffan
Sundin, Anders
Crona, Joakim
author_facet Mollazadegan, Kazhan
Skogseid, Britt
Botling, Johan
Åkerström, Tobias
Eriksson, Barbro
Welin, Staffan
Sundin, Anders
Crona, Joakim
author_sort Mollazadegan, Kazhan
collection PubMed
description Longitudinal changes in pancreatic neuroendocrine tumor (panNET) cell proliferation correlate with fast disease progression and poor prognosis. The optimal treatment strategy for secondary panNET grade (G)3 that has progressed from a previous low- or intermediate-grade to high-grade panNET G3 is currently unknown. This was a single-center retrospective cohort study aimed to characterize treatment patterns and outcomes among patients with secondary panNET-G3. Radiological responses were assessed using the Response Evaluation Criteria in Solid Tumors version 1.1. A total of 22 patients were included and received a median of 2 (range, 1–4) treatment lines in 14 different combinations. Median overall survival (OS) was 9 months (interquartile range (IQR): 4.25–17.5). For the 15 patients who received platinum–etoposide chemotherapy, median OS was 7.5 months (IQR: 3.75–10) and median progression-free survival (PFS) was 4 months (IQR: 2.5–5.5). The 15 patients who received conventional panNET therapies achieved a median OS of 8 months (IQR: 5–16.75) and median PFS was 5.5 months (IQR: 2.75–8.25). We observed one partial response on (177)Lu DOTA-TATE therapy. In conclusion, this hypothesis-generating study failed to identify any promising treatment alternatives for patients with secondary panNET-G3. This demonstrates the need for both improved biological understanding of this particular NET entity and for designing prospective studies to further assess its treatment in larger patient cohorts.
format Online
Article
Text
id pubmed-8942326
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-89423262022-03-28 Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors Mollazadegan, Kazhan Skogseid, Britt Botling, Johan Åkerström, Tobias Eriksson, Barbro Welin, Staffan Sundin, Anders Crona, Joakim Endocr Connect Research Longitudinal changes in pancreatic neuroendocrine tumor (panNET) cell proliferation correlate with fast disease progression and poor prognosis. The optimal treatment strategy for secondary panNET grade (G)3 that has progressed from a previous low- or intermediate-grade to high-grade panNET G3 is currently unknown. This was a single-center retrospective cohort study aimed to characterize treatment patterns and outcomes among patients with secondary panNET-G3. Radiological responses were assessed using the Response Evaluation Criteria in Solid Tumors version 1.1. A total of 22 patients were included and received a median of 2 (range, 1–4) treatment lines in 14 different combinations. Median overall survival (OS) was 9 months (interquartile range (IQR): 4.25–17.5). For the 15 patients who received platinum–etoposide chemotherapy, median OS was 7.5 months (IQR: 3.75–10) and median progression-free survival (PFS) was 4 months (IQR: 2.5–5.5). The 15 patients who received conventional panNET therapies achieved a median OS of 8 months (IQR: 5–16.75) and median PFS was 5.5 months (IQR: 2.75–8.25). We observed one partial response on (177)Lu DOTA-TATE therapy. In conclusion, this hypothesis-generating study failed to identify any promising treatment alternatives for patients with secondary panNET-G3. This demonstrates the need for both improved biological understanding of this particular NET entity and for designing prospective studies to further assess its treatment in larger patient cohorts. Bioscientifica Ltd 2022-02-11 /pmc/articles/PMC8942326/ /pubmed/35148276 http://dx.doi.org/10.1530/EC-21-0604 Text en © The authors https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Research
Mollazadegan, Kazhan
Skogseid, Britt
Botling, Johan
Åkerström, Tobias
Eriksson, Barbro
Welin, Staffan
Sundin, Anders
Crona, Joakim
Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors
title Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors
title_full Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors
title_fullStr Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors
title_full_unstemmed Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors
title_short Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors
title_sort poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942326/
https://www.ncbi.nlm.nih.gov/pubmed/35148276
http://dx.doi.org/10.1530/EC-21-0604
work_keys_str_mv AT mollazadegankazhan pooroutcomeaftersystemictherapyinsecondaryhighgradepancreaticneuroendocrinetumors
AT skogseidbritt pooroutcomeaftersystemictherapyinsecondaryhighgradepancreaticneuroendocrinetumors
AT botlingjohan pooroutcomeaftersystemictherapyinsecondaryhighgradepancreaticneuroendocrinetumors
AT akerstromtobias pooroutcomeaftersystemictherapyinsecondaryhighgradepancreaticneuroendocrinetumors
AT erikssonbarbro pooroutcomeaftersystemictherapyinsecondaryhighgradepancreaticneuroendocrinetumors
AT welinstaffan pooroutcomeaftersystemictherapyinsecondaryhighgradepancreaticneuroendocrinetumors
AT sundinanders pooroutcomeaftersystemictherapyinsecondaryhighgradepancreaticneuroendocrinetumors
AT cronajoakim pooroutcomeaftersystemictherapyinsecondaryhighgradepancreaticneuroendocrinetumors